Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

PLUS vs DBD: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

PLUS Captures Overall Composite Edge (47.6 HOLD vs 50.6 HOLD), While DBD Leads 4–2 on Growth & Valuation Pillars

PLUS Overall Winner 6-Pillar Tally: PLUS 2 – 4 DBD Matrix Metrics: PLUS 7 – 3 DBD

As of Nov 20, 2026, ePlus Inc (PLUS) captures the overall head-to-head institutional edge over Diebold Nixdorf, Incorporated (DBD) on higher Unified Composite conviction (47.6/100 HOLD vs. 50.6/100 HOLD) after splitting the core matrix 7–3 (led by Growth & Scale, R&D & Supply-Chain Moat), while DBD wins 4–2 across the 6-pillar growth and valuation breakdown. PLUS trades at $92.13 (16.6x Forward P/E, 6.8% operating margin) versus DBD at $51.86 (8.4x Forward P/E, 9.0% operating margin).

  • Composite vs. Pillar Nuance: While DBD currently prints a higher short-term Unified Composite Score (50.6/100 HOLD vs. PLUS 47.6/100 HOLD), PLUS captures the overall institutional head-to-head verdict (7–3 matrix metrics and 2–4 across the 6 pillars) due to superior fundamental profitability (6.8% vs. 9.0% operating margin) and revenue trajectory (+9.7% vs. +5.2% YoY).
  • Technical & Structure Timing Caution: PLUS trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 46.2); meanwhile DBD is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 32.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About PLUS vs DBD
PLUS NASDAQ Head-to-Head Winner
ePlus Inc
Wholesale-Computers & Peripheral Equipment & Software
$92.13
-3.67% 1D
Market Cap $2.5B
TTM Revenue $2.51B
Forward P/E 16.6x
Beta / 30D Vol 0.89β · 58% Vol
Unified Composite Score
47.6 / 100 HOLD
Tech 47.0 Fund 44.0 Flow 55.0 Mom 30.9
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 46
RSI-14: 46.2 · SMA20: $93.86 · SMA50: $93.25
DBD NYSE
Diebold Nixdorf, Incorporated
Calculating & Accounting Machines (No Electronic Computers)
$51.86
+3.16% 1D
Market Cap $1.7B
TTM Revenue $3.92B
Forward P/E 8.4x
Beta / 30D Vol 0.91β · 60% Vol
Unified Composite Score
50.6 / 100 HOLD
Tech 58.0 Fund 59.0 Flow 67.0 Mom 60.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -6.7%), weak momentum, RSI 33
RSI-14: 32.7 · SMA20: $56.94 · SMA50: $61.52

6-Pillar Scorecard Institutional Category Breakdown (PLUS 2 – 4 DBD)

Columns: Metric · PLUS · DBD
1. Valuation Multiples DBD
Forward P/E 16.6x 8.4x
Trailing P/E 20.1x 23.8x
PEG Ratio 1.18x N/M
EV / Revenue 0.9x 0.6x
2. Growth & Scale PLUS
Revenue Growth (YoY) +9.7% +5.2%
Earnings Growth (YoY) +18.0% -82.9%
TTM Revenue (USD) $2.51B $3.92B
Market Cap $2.5B $1.7B
3. Profitability & Quality DBD
Gross Margin 25.2% 26.0%
Operating Margin 6.8% 9.0%
Net Profit Margin 5.0% 2.0%
Return on Equity (ROE) 11.6% 7.7%
4. Balance Sheet & Cash Flow DBD
Cash Generation (TTM) $32M $127M
Cash Flow Margin 1.3% 3.2%
Net Cash / Leverage $242M Net Cash $764M Net Debt (1.01x D/E)
Dividend Yield 1.07% None (0.00%)
5. Options & Positioning DBD
Options Structure Phase CONSOLIDATION BREAKDOWN
Current IV / %ile 173.5% (100th %ile) 38.9% (9th %ile)
Put/Call OI Skew N/A 1.24x (Put-Skewed)
OBV Trend / Tech Phase DISTRIBUTION · Neutral DISTRIBUTION · Markdown
6. R&D & Supply-Chain Moat PLUS
OpEx & R&D Intensity 18.4% of Rev ($461M) 17.0% of Rev ($667M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Software - Application Operator Software - Application Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: PLUS (7) vs DBD (3)
Institutional Metric PLUS DBD Criterion Row Edge
Market Capitalization
Scale
$2.5B $1.7B Larger Scale PLUS
Trailing P/E Ratio
Valuation
20.1x 23.8x Lower Multiple PLUS
Forward P/E Ratio
Valuation
16.6x 8.4x Lower Multiple DBD
Revenue Growth (YoY)
Growth
+9.7% +5.2% Higher Growth PLUS
Operating Margin (TTM)
Profitability
6.8% 9.0% Higher Margin DBD
Net Profit Margin
Profitability
5.0% 2.0% Higher Margin PLUS
Return on Equity (ROE)
Capital Efficiency
11.6% 7.7% Higher ROE PLUS
52-Week Range Position
Momentum
72% ($73–$100) 5% ($50–$92) Stronger Trend PLUS
Beta / 30D Volatility
Risk Regime
0.89β · 58% Vol 0.91β · 60% Vol Lower Realized Risk PLUS
Unified Institutional Score
Composite Signal
47.6 / 100 (HOLD) 50.6 / 100 (HOLD) Higher Composite DBD
Trailing 12M Revenue (USD)
Operating Scale
$2.51B $3.92B FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
25.2% 26.0% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
1.18x PEG · 0.9x EV/Rev N/M PEG · 0.6x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
$32M ($242M Net Cash) $127M ($764M Net Debt (1.01x D/E)) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon PLUS +20.94 pp
PLUS: -4.18% · DBD: -25.12%
3M Horizon PLUS +31.43 pp
PLUS: +6.81% · DBD: -24.62%
6M Horizon PLUS +38.12 pp
PLUS: +7.92% · DBD: -30.2%
1Y Horizon PLUS +19.73 pp
PLUS: +3.16% · DBD: -16.57%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period PLUS Revenue DBD Revenue PLUS Op. Margin DBD Op. Margin Margin Leader
FY2019 $1.37B $4.41B 5.8% -0.6% PLUS
FY2020 $1.59B $3.90B 6.0% 0.6% PLUS
FY2021 $1.57B $3.91B 6.8% 3.5% PLUS
FY2022 $1.82B $3.46B 8.1% -6.1% PLUS
FY2023 $2.07B N/A 8.0% N/A PLUS
FY2024 $2.18B $3.75B 6.1% 4.9% PLUS
FY2025 $2.00B $3.81B 5.0% 6.4% DBD
FY2026 $2.44B N/A 6.8% N/A PLUS

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
PLUS CONSOLIDATION
136d in phase · OBV DISTRIBUTION
Current IV 173.5%
IV Percentile 100th %ile
Put/Call OI Skew N/A
IV Regime Extreme (>80th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow DISTRIBUTION
Exact PLUS Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
DBD BREAKDOWN
82d in phase · OBV DISTRIBUTION
Current IV 38.9%
IV Percentile 9th %ile
Put/Call OI Skew 1.24x (Put-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow DISTRIBUTION
Exact DBD Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
PLUS Moat Profile Cyclical / Execution-Driven Positioning
Software - Application Operator
Competes within the Software - Application value chain with $2.5B market capitalization and 6.8% operating margin.
OpEx & R&D Reinvestment 18.4% of Rev ($461M)
90D Engineering Disclosures 0 Published
DBD Moat Profile Cyclical / Execution-Driven Positioning
Software - Application Operator
Competes within the Software - Application value chain with $1.7B market capitalization and 9.0% operating margin.
OpEx & R&D Reinvestment 17.0% of Rev ($667M)
90D Engineering Disclosures 0 Published

Investor FAQ PLUS vs DBD Key Questions & Quantitative Answers

As of Nov 20, 2026, ePlus Inc (PLUS) captures the overall head-to-head institutional edge over Diebold Nixdorf, Incorporated (DBD) on higher Unified Composite conviction (47.6/100 HOLD vs. 50.6/100 HOLD) after splitting the core matrix 7–3 (led by Growth & Scale, R&D & Supply-Chain Moat), while DBD wins 4–2 across the 6-pillar growth and valuation breakdown. PLUS trades at $92.13 (16.6x Forward P/E, 6.8% operating margin) versus DBD at $51.86 (8.4x Forward P/E, 9.0% operating margin). Composite vs. Pillar Nuance: While DBD currently prints a higher short-term Unified Composite Score (50.6/100 HOLD vs. PLUS 47.6/100 HOLD), PLUS captures the overall institutional head-to-head verdict (7–3 matrix metrics and 2–4 across the 6 pillars) due to superior fundamental profitability (6.8% vs. 9.0% operating margin) and revenue trajectory (+9.7% vs. +5.2% YoY). Technical & Structure Timing Caution: PLUS trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 46.2); meanwhile DBD is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 32.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

PLUS leads the Growth & Scale pillar: PLUS posts +9.7% YoY revenue growth and +18.0% YoY earnings growth on $2.51B TTM revenue (25.2% gross margin, 6.8% operating margin), compared with DBD at +5.2% YoY revenue growth and -82.9% YoY earnings growth on $3.92B TTM revenue (26.0% gross margin, 9.0% operating margin). Across the 8-period historical trajectory (FY2019 to FY2026), PLUS cumulative revenue shifted +78.1% while DBD shifted -13.6%. In operating R&D and SG&A reinvestment, PLUS deploys 18.4% of Rev ($461M) (0 90-day corporate R&D disclosures) versus 17.0% of Rev ($667M) (0 disclosures) for DBD.

DBD screens cheaper on headline valuation multiples. PLUS trades at 16.6x Forward P/E, 20.1x Trailing P/E, 1.18x PEG, and 0.9x EV/Revenue (1.3% FCF margin), whereas DBD trades at 8.4x Forward P/E, 23.8x Trailing P/E, N/M PEG, and 0.6x EV/Revenue (3.2% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against PLUS (11.6% ROE) versus DBD (7.7% ROE) capital efficiency.

In options market volatility and institutional positioning, PLUS carries 173.5% implied volatility (100th %ile, Extreme (>80th %ile)), unclassified Put/Call open interest, DISTRIBUTION on-balance volume, and sits in a CONSOLIDATION options structure phase (0.89β · 58% Vol realized risk). By comparison, DBD carries 38.9% implied volatility (9th %ile, Compressed (<25th %ile)), a 1.24x (Put-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (0.91β · 60% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.